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Abstract
Background: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral
treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the
primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity.
Methodology/Principal Findings: Study participants were 1809 HIV-infected, antiretroviral naı ¨ve adults initiating
nevirapine-based antiretroviral therapy between November 2002 and December 2006. The primary outcome was early
hepatotoxicity. Secondary outcomes were associations with hepatotoxicity and mortality at six months. The cumulative
proportion of early hepatotoxicity ranged from 1.0–2.0% giving an incidence-rate at 102 days of 3.6–7.6 per 100 person-
years. Median time to hepatotoxicity was 32 (IQR 28–58) days. At 12 weeks, only 8% of patients had alanine
aminotransferase monitoring at all the time-points recommended by national guidelines. No association was found
between age, gender, baseline CD4 count, concurrent tuberculosis infection, prior participation in a prevention of mother-
to-child-transmission program, or baseline weight and early hepatotoxicity. There was no association between early
hepatotoxicity and mortality.
Conclusions: The cumulative proportion of early hepatotoxicity in nevirapine based antiretroviral therapy was low in this
resource-constrained setting. Hepatotoxicity was not associated with mortality. Frequent routine monitoring of alanine
aminotransferase proved difficult to implement in this public sector primary care programme. Focused monitoring in the
first month may be a more cost-effective and pragmatic option in settings with limited resources. Correlation with clinical
signs and symptoms may allow future alanine aminotransferase testing to be dictated by clinical criteria.
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Introduction
The majority of antiretroviral treatment programmes in sub-
Saharan Africa are scaling up antiretroviral treatment (ART) using
a fixed dose first-line antiretroviral regimens containing stavudine,
lamivudine and nevirapine (NVP) [1,2]. One of the primary
concerns with the use of this regimen is nevirapine-associated
hepatotoxicity (HT) [3,4,5,6,7,8,9,10]. In resource rich countries,
screening for HT during ART has been primarily based on serum
level of alanine aminotransferase (ALT), a liver enzyme which
serves as a ‘‘proxy’’ for liver inflammation and damage. Clinical
guidelines recommend discontinuation of NVP at grade 3 or 4 HT
[11]. ALT testing requires laboratory technology that is sophisti-
cated and expensive and therefore not routinely available at the
health-centre level in most resource-poor countries. In order to
encourage a simplified approach to scaling up antiretroviral
treatment, WHO Guidelines do not insist on ALT monitoring as
a pre-requisite to ART provision at the primary care level, and
recommendations for frequency of testing when it is available are
unclear [1]. This, however, is in contrast to manufacturer guidelines
that recommendvigilantALTmonitoringforNVPusersforthe first
18 weeks,and regular monitoring thereafter whilst ontreatment [3].
Clinical trials support routine monitoring in the first 12 weeks
[6,12,13], but it is unknown if routine ALT testing prevents
morbidity or mortality in routine programme settings.
Alcohol and hepatitis C co-infection are well established risk
factors for hepatotoxicity but the effects of other host characteristics
are not well studied [14,15]. While early clinical trials conducted in
resource rich-settings found that female gender and baseline CD4
cell counts above 250 cells/ml are risk factors for hepatotoxicity,
results from other studies are conflicting [6,16,17,18].
In clinical trials, mostly conducted in resource-rich countries,
NVP- associated HT ranges from 8–18% [7,9,14]. NVP-
associated HT in routine programme settings in Africa appears
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represent the risk of HT because of limited ALT monitoring. The
objectives of this study were to describe the incidence, risk factors,
and associated mortality due to hepatotoxicity in a primary care
ART programme in South Africa with frequent ALT monitoring.
Methods
Study Setting
This study included patients from three primary care HIV
clinics in Khayelitsha township, South Africa, where antiretroviral
treatment (ART) has been provided by Me ´decins Sans Frontie `res
(MSF) since 2001 in collaboration with the Provincial Department
of Health. These clinics follow national South African treatment
guidelines which comply with WHO guidelines: all patients were
started on either NVP or EFV-based ART. NVP-based regimens
were initiated with the recommended lead-in dose of NVP 200 mg
daily for 14 days followed by NVP 200 mg twice daily. ALT
testing was offered to patients starting NVP-based ART at
baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks then
every 6 months thereafter. Specimens for laboratory testing were
transported the same day to a single regional laboratory run by the
National Health Laboratory Services which applied stringent
quality control measures. ALT assays were conducted using a
spectrophotometer following standard operating procedures.
Inclusion and Exclusion Criteria
All patients initiating NVP-based ART from November 2002
(when ALT testing became available) until the end of December
2006 and who were on NVP for at least four weeks were considered
for analysis. For the analysis of HT, patients were stratified into two
groups: those who had ALT monitoring for at least 4 weeks at all
time points recommended by national guidelines (complete
monitoring) and those with incomplete monitoring. Those who
were treatment-experienced and children under 16 years old were
excluded. Women who had previously received single or dual NVP-
based therapy via the prevention of mother to child transmission
(PMTCT) program were also included.
Definitions
Serum ALT was graded according to criteria established by the
AIDS Clinical Trial Group [22]: grade 0: ,1.25x upper limit of
normal (ULN); grade 1: 1.25–2.5x ULN; grade 2: 2.6–5.0x ULN,
grade 3: 5.1–10x ULN; grade 4: .10x ULN. Baseline ALT was
defined as any measurement between 90 days prior to 6 days after
ART initiation; four week ALT was any measurement between 7
and 41 days after ART initiation; 8 week ALT between 42 and 69
days after ART initiation, and 12 week ALT between 70 and 102
days after ART initiation. Since few patients had ALT measure-
ments at 2 weeks, these were combined with the 4 week
measurements. If more than one ALT was measured during the
visit time, the highest ALT was used. Early hepatotoxicity was
defined as an increase in ALT from grade 0–2 at baseline to grade 3
or 4 within 102 days of starting ART.
Time on NVP and Mortality
Patient time on NVP was calculated from treatment com-
mencement to HT or until the drug was stopped or substituted for
other reasons. Mortality was evaluated up to 6 months after
initiation of NVP-based ART.
Statistical Analysis
Data was exported from a database prospectively maintained
for routine monitoring and evaluation. Serum ALT values were
obtained from the laboratory and merged using Stata (Version 10,
College Station, TX, USA). Baseline characteristics were de-
scribed using medians and interquartile ranges (IQRs) for
continuous variables and counts and percentages for categorical
data. Means were compared using the student’s t-test and
proportions using the chi squared test. Person-time of observation
were accrued from the initiation on NVP-based ART until either
occurrence of death, loss to follow-up, transfer to another ART
programme or censoring of observation in July 2007. Kaplan–
Meier analysis was used to estimate cumulative HT. Cox
proportional hazards were used to determine associations between
baseline characteristics and HT and mortality. Logistic regression
was used to determine associations between baseline characteris-
tics and grade 3 or 4 ALT baseline elevation. Variables considered
in the analysis for early HT and baseline ALT elevation included
age, gender, baseline CD4 cell count (cells/ml), increase in CD4
count .100 cells/ml at 6 months, baseline weight less than 60 kg,
concurrent TB treatment, and prior prevention of mother-to-child
transmission (PMTCT) program enrolment. Early HT was also
considered in the analysis for mortality. All tests and confidence
intervals (CI) were considered to be significant at a p#0.05 (two-
sided). An additional chart review was conducted on patients with
early HT to obtain information on viral hepatitis testing,
associated symptoms, outcome of HT, drug regimen changes,
and death attributable to HT.
Ethics
Procedures for selection and inclusion of patients within the
ARV program followed the national guidelines for the implemen-
tation and roll-out of ART. General measures were provided to
ensure patient confidentiality, consent for HIV testing, and
counselling and support for those who receive a positive HIV
test results. ART and all laboratory testing services (including
ALT) were offered free of charge. The University of Cape Town
ethics committee gave approval for this study without requiring
patient consent because the analysis was based on routine clinical
data. No additional data were collected specifically for this study,
and the data were fully de-identified prior to analysis.
Results
Patient Characteristics
From November 2002 to December 2006, 3728 HIV-infected,
ART-naı ¨ve individuals were initiated on ART. Of these, 1831
(49%) were started on NVP- based first-line therapy; 1809 (99%)
remained on NVP at 4 weeks. Of these 911 (50%) patients had at
least a baseline and a 4 week ALT measurement (complete
monitoring) and 898 (50%) had either a missing baseline or 4 week
ALT measurement (incomplete monitoring). Patient characteris-
tics of both these groups on NVP are shown in Table 1. The
median baseline CD4 count was 112 (IQR 57–164) cells/ml. In the
group with complete ALT monitoring, there were 216 (24%)
males compared to 167 (19%) in the group with incomplete
monitoring (p=0.008), and the median follow-up time on NVP-
based ART was 18 (IQR 8–26) months compared to 9 (IQR 5–19)
months respectively (p,0.001).
ALT Grades and Baseline ALT Elevation
Of the 1831 patients on NVP at baseline, 1444 (79%) patients
had a baseline ALT measurement. Of the 1809 patients on NVP
at 4 weeks, 911(50%) had ALT measured at baseline and 4 weeks.
Of the 1705 patients on NVP at 8 weeks, 368 (22%) had complete
ALT monitoring (baseline, 4 and 8 weeks), and at 12 weeks, only
127 (8%) had all recommended ALT monitoring (baseline, 4, 8,
Nevirapine Hepatotoxicity
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9183and 12 weeks). ALT grades for these visits (0, 4, 8, and 12 weeks)
are shown in Table 2. Eighty-eight percent of ALT measurements
were not elevated (grade 0). Eight (0.6%) of 1444 patients had a
baseline grade 3 or 4 ALT elevation. Of those with grade 3 or 4
baseline transaminitis, 4 (50%) continued NVP-based ART. Of
these, all (100%) resolved their ALT elevations after 4 weeks.
Baseline CD4 cell count ,50 cells/ml was the only variable
associated with baseline grade 3 or 4 transaminitis (unadjusted
OR=5.99, 95% CI 1.42–25.1) (data not shown).
Hepatotoxicity
Twenty-six patients developed early HT. The median time to
early HT was 32 (IQR 28–63) days. Among patients who had
complete ALT monitoring, the cumulative proportion of early HT
was 2.0% by 102 days on NVP giving an incidence rate of 7.6 (95%
CI: 4.8–12.1)per100 person-years overthis period. The cumulative
proportion with HT in patients with incomplete ALT monitoring
was 1.0% by 102 days on NVP giving an incidence-rate of 3.6 (95%
CI: 1.8–7.2) per 100 person-years over this period (Figure 1).
Of the 26 patients with early HT, 14 (54%) had grade 3 HT and
12 (46%) had grade 4 HT. Four (15%) were being treated for
active tuberculosis. Eight (31%) inadvertently continued NVP-
based ART of which 7 (88%) resolved their HT and one was
LTFU. Of the 18 who stopped NVP, all switched to efavirenz
(EFV) based-ART. Of these, 2 (12%) developed further HT on
EFV. Symptoms were known for 17 (65%). Of these 8 (47%) had
either a rash or symptoms consistent with hepatitis (Table 3).
Eleven additional patients developed late hepatotoxcity (after 12
weeks) between 121–891 days.
Risk Factors for Hepatotoxicity
There were no associations found between baseline character-
istics and hepatotoxicity including gender (adjusted hazards ratio,
AHR=1.2, P=0.756), age (AHR=1.0, P=0.540), baseline CD4
Table 1. Characteristics of patients on nevirapine-based antiretroviral treatment*.
Characteristics Total Cohort Complete ALT Monitoring** Incomplete ALT Monitoring*** p
Total on NVP at 4 weeks 1809 911 (50) 898 (50)
Males 383 (21) 216 (24) 167 (19) 0.008
Age on starting NVP based ART, years 32 (28–37) 32 (28–38) 31 (27–37) 0.989
Baseline CD4+ count, cell/ml 112 (57–164) 117 (63–166) 107 (49–163) 0.972
Baseline viral load, log10 copies 5.0 (4.5–5.5) 5.0 (4.4–5.5) 5.0 (4.5–5.5) 0.161
WHO clinical staging on starting ART
Stage 1 169 (9) 76 (8) 84 (9) 0.449
Stage 2 194 (11) 91 (10) 103 (11) 0.309
Stage 3 922 (51) 467 (51) 455 (51) 0.800
Stage 4 533 (29) 277 (30) 256 (28) 0.376
Weight on starting ART, kg 60 (53–69) 60 (53–69) 60 (53–69) 0.437
Follow-up time on NVP-based ART, months 13 (6–22) 18 (8–26) 9 (5–19) ,0.001
6 month mortality 73 (4) 16 (2) 57 (6) ,0.001
Continuous variables are given as medians (interquartile range). Ordinal and discrete variables are given as n(%). NVP, Nevirapine. ART, antiretroviral therapy. WHO,
World Health Organization.
*On NVP for at least 4 weeks.
**Patients with at least baseline and 4 week ALT.
***Patients without baseline or 4 week ALT.
doi:10.1371/journal.pone.0009183.t001
Table 2. Alanine aminotransferase for patients with complete monitoring.
Baseline (%) 4 weeks (%) 8 weeks (%) 12 weeks (%)
On NVP 1831 1809 1705 1665
Complete ALT monitoring* 1444 (79) 911 (50) 368 (22) 127 (8)
ALT Grade 0 1314 (90) 779 (86) 321 (87) 105 (83)
ALT Grade 1 110 (8) 86 (9) 33 (9) 17 (13)
ALT Grade 2 13 (1) 32 (4) 9 (2) 3 (2)
ALT Grade 3 6 (0.4 5 (0.6) 3 (0.8) 2 (2)
ALT Grade 4 2 (0.1) 9 (0.1) 2 (0.5) 0 (0)
*Patients who had ALT monitoring according to South African guidelines up to the time of consultation. The guidelines recommend ALT at 0, 4, 8, and 12 weeks.
All variables are given as n(%). NVP, nevirapine. ALT, alanine liver transferase. ALT grade 0:,1.25x upper limit of normal (ULN); grade 1: 1.25–2.5x ULN; grade 2: 2.6–5.0x
ULN, grade 3: 5.1–10x ULN; grade 4: .10x ULN.
doi:10.1371/journal.pone.0009183.t002
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cells/ml at 6 months (AHR=0.9, P=0.489). (Table S1).
Mortality
Seventy-three (4%) of 1809 patients died within 6 months of
starting NVP based ART. In patients with at least baseline and 4
week ALT measurements (complete monitoring), 16/911 (2%)
died in the first 6 months. In this group, 18/911 patients had early
HT, of whom 2/18 (11%) died. One of these deaths was HT-
related. In the patients with incomplete ALT monitoring, 57/898
(6%) died in the first 6 months. In this group, 8/898 had early HT,
of whom one (12%) died, of non-HT causes. All three patients who
died with early HT had grade 4 ALT elevations. There was no
mortality at 6 months in patients who developed late HT.
Baseline CD4 count .100 cells/ml was protective against mortality
(AHR=0.44, P,0.001) on multivariate analysis. Variables not
associated with mortality included age (AHR=1.3, P=0.412), gender
(AHR=1.0, P=0.345), HT (AHR=2.5, P=0.126), ALT elevation at
baseline (AHR=2.4, P=0.383), current TB status (unadjusted
HR=0.9, P=0.807), and PMTCT attendance (unadjusted
HR=0.9, P=0.184). (Table S2).
Discussion
The cumulative proportion of early HT was 1.0–2.0% and not
associated with increased mortality. This is comparable to low
incidence proportions reported by Hahn et al (2.2%) from an
ARV program in Uganda and Meyssonnier et al (1.2%) in a
program from Niger [18,20]. In contrast, clinical trials with serial
ALT testing have reported higher HT. For example, in the
Boehringer Ingelheim trial, of 2545 patients on NVP, 10%
developed HT at one year [7] and in a South African trial 17%
developed HT within 3 months [6].
Programmatic ALT monitoring was enforced in less than one
tenth of patients at 3 months. This highlights the difficulty of
implementing serial ALT monitoring in high-burden public
sector clinics. Even when monitoring schedules were adhered
to, the proportion of patients with severe hepatotoxicity was
very low. Furthermore, patients with ALT elevations who were
also symptomatic could have been identified by their symp-
toms. Finally, many patients who had HT by ALT elevation
were left on NVP due to administrative delays in receiving the
laboratory results and subsequently revert to normal levels.
This study did not demonstrate that ALT monitoring according
to national guidelines adverted severe or fatal hepatotoxicity.
The one HT-related death occurred in a patient with complete
monitoring.
The medium time to early HT was 32 days and was consistent
with other studies [6,23]. Time to late HT (after 12 weeks) was
highly variable and did not account for any additional mortality.
This suggests programmatic ALT monitoring is most valuable in
the first month and continued testing after 12 weeks can be of
lower priority in resource constrained settings.
We did not identify any risk factors for HT. In particular, a
higher CD4 was not associated with HT. This contrasts with
previous findings that men and women with CD4 counts greater
than 400 cells/ml and 250 cells/ml, respectively, are at greatest risk
[24]. In sub-Saharan Africa, especially in the programmatic
setting, baseline CD4 counts are generally much lower than in
resource-rich countries because of difficulties in accessing care
[25]. Because our median CD4 count was low (112 cells/ml [IQR
57–164]) we may not have been able to demonstrate this
association. However, recent studies with higher median CD4
counts suggest that CD4 count is not associated with HT [17,18].
Patient gender was not a risk factor for HT. This agrees with
results from other programmatic settings [16,23] but conflicts with
clinical trials [6].
This study had a number of strengths and limitations. First, this is
one of the largest cohorts of patients on NVP-based ART in southern
Africa.Second,laboratoryALTvalueswereusedtodetermineHTso
misclassification was unlikely. Finally, the availability of a group with
complete ALT monitoring allowed calculation of ALT grades by
weeks on NVP. The main limitation was that there were many
patients with incomplete ALT monitoring and transient HT may
have been missed which likely accounted for the lower incidence rate
of early HT in this group. However, the incidence rate in the group
with complete monitoring likely reflects true early HT. Another
limitation was that other risk factors for HT such as alcohol use and
Figure 1. Cumulative early hepatotoxicity stratified by ALT monitoring.
doi:10.1371/journal.pone.0009183.g001
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confounded the overall incidence estimate: rates of hepatitis co-
infection reported in South Africa [26] are lower than settings where
hepatitis co-infection has been found to be a risk factor [5]. Low BMI
has been reported as a risk factor [6]; this could not be assessed in our
study as height was not routinely recorded. Finally, data on clinical
manifestations of NVP hypersensitivity were incomplete.
We believe our findings have important public health
implications regarding ALT monitoring and the risk of nevir-
apine-based ART regimens. The risk of life-threatening hepato-
toxicity has led NVP manufacturers to warn against its use without
close serological and clinical monitoring and in the US and
Europe serial serum ALT testing is routine. In resource-limited
settings such as in sub-Saharan Africa where NVP is the mostly
commonly used NNRTI, ALT monitoring is expensive and often
technologically not feasible and its use in routine programmes
needs to be carefully considered. In our cohort in South Africa, the
incidence rate of early HT is low in this population with a low
median baseline CD4 count. Routine ALT monitoring was not
consistently implemented and not associated with mortality.
Taking into account these considerations, focused monitoring in
the first month may be a more cost-effective and pragmatic option
in settings with limited resources. Correlation with clinical signs
and symptoms may allow future ALT testing to be dictated by
clinical criteria.
Supporting Information
Table S1 Associations between patient characteristics and
hepatotoxicity.
Found at: doi:10.1371/journal.pone.0009183.s001 (0.06 MB
DOC)
Table S2 Associations between patient characteristics and
mortality.
Found at: doi:10.1371/journal.pone.0009183.s002 (0.06 MB
DOC)
Acknowledgments
We would like to thank Line Arnould for inspiring this research study.
Author Contributions
Conceived and designed the experiments: KMC GVC. Analyzed the data:
KMC AMB NF GVC. Contributed reagents/materials/analysis tools: EG.
Wrote the paper: KMC AMB NF EG VA GVC.
Table 3. Patients with early hepatotoxicity on nevirapine-based antiretroviral treatment.
Patient
Number Age Gender
Baseline
CD4
6
month
CD4
Grade
HT
ALT
Monitoring
Tuberculosis
co-infection Symptoms
Viral
Hepatitis
co-infection
NNRTI
after HT
diagnosis
Outcome
of HT
6 month
patient
outcome
1 50 Female 100 4 Complete No Rash Not excluded EFV Resolved Dead, HT
2 26 Female 189 605 4 Complete No No Excluded EFV Resolved Alive
3 32 Female 4 3 Complete No No Not excluded NVP Resolved Alive
4 29 Female 219 358 3 Complete No Unknown Not tested NVP Resolved Alive
5 28 Female 191 4 Complete No Rash and hepatitis Excluded EFV Resolved LTFU
6 30 Female 190 320 4 Complete No Unknown Not tested EFV Resolved Alive
7 28 Female 172 266 4 Complete No Hepatitis Excluded EFV Resolved Alive
8 32 Female 178 682 4 Complete No No Not excluded EFV Resolved Alive
9 48 Female 79 4 Complete Yes No Not excluded EFV Resolved Dead, not HT
10 35 Male 100 210 4 Complete No Rash Not excluded EFV Resolved Alive
11 38 Male 154 283 3 Complete No No Not excluded EFV Resolved Alive
12 25 Female 92 245 3 Complete No No Excluded EFV Continued Alive
13 48 Female 47 74 3 Complete No Unknown Not tested EFV Resolved Alive
14 48 Male 5 116 3 Complete No Unknown Not tested EFV Resolved Alive
15 23 Male 29 89 3 Complete Yes Unknown Not tested NVP Resolved Alive
16 41 Female 190 405 4 Complete No No Not excluded NVP Resolved Alive
17 28 Female 60 4 Complete No Unknown Not tested EFV Resolved Alive
18 32 Female 36 413 3 Complete No Rash Not excluded NVP Resolved Alive
19 34 Female 66 4 Incomplete Yes Rash Not excluded EFV Resolved Dead, not HT
20 36 Female 134 271 3 Incomplete No Rash Not excluded NVP Resolved Alive
21 31 Male 180 423 3 Incomplete No Unknown Not tested EFV Resolved Alive
22 30 Male 2 4 Incomplete No Unknown Not tested EFV Continued Alive
23 38 Female 78 3 Incomplete No No Not excluded EFV Resolved Alive
24 37 Female 41 179 3 Incomplete Yes No Not excluded NVP Resolved Alive
25 36 Female 217 3 Incomplete No Rash Excluded EFV Resolved Alive
26 33 Female 148 286 3 Incomplete No Unknown Not tested NVP Resolved Alive
HT, Hepatotoxicity. ALT, alanine aminotransferase. NNRTI, non-nucleoside reverse transcriptase inhibitor. EFV, efavirenz. NVP, nevirapine.
doi:10.1371/journal.pone.0009183.t003
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